Guidelines for the diagnosis and treatment of pulmonary hypertension by, Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery,

Slides:

Advertisements

Similar presentations

Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and post- pulmonary endarterectomy pulmonary hypertension A pre-defined subgroup.

Advertisements

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies by Lawrence de Koning,

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 by, John J.V. McMurray, Stamatis Adamopoulos, Stefan D. Anker, Angelo.

B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode by Guillaume.

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,

Guidelines on diagnosis and treatment of pulmonary arterial hypertension by Nazzareno Galiè, Adam Torbicki, Robyn Barst, Philippe Dartevelle, Sheila Haworth,

Guidelines on myocardial revascularization by,, William Wijns, Philippe Kolh, Nicolas Danchin, Carlo Di Mario, Volkmar Falk, Thierry Folliguet, Scot Garg,

Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a.

Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia by András Vereckei, Gábor Duray, Gábor Szénási, Gregory T.

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure by Markku S. Nieminen, Michael Böhm, Martin R. Cowie, Helmut.

Guidelines on the diagnosis and management of acute pulmonary embolism by, Adam Torbicki, Arnaud Perrier, Stavros Konstantinides, Giancarlo Agnelli, Nazzareno.

Coronary computed tomography angiography with a consistent dose below 1 mSv using prospectively electrocardiogram-triggered high-pitch spiral acquisition.

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)‏ by,, Gilbert Habib, Bruno Hoen, Pilar Tornos, Franck.

Guidelines for the diagnosis and treatment of non-ST- segment elevation acute coronary syndromes by Jean-Pierre Bassand, Christian W. Hamm, Diego Ardissino,

Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment.

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with.

Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay:

The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator by Guiqing Yao, Nick Freemantle,

Guidelines for cardiac pacing and cardiac resynchronization therapy by Panos E. Vardas, Angelo Auricchio, Jean-Jacques Blanc, Jean-Claude Daubert, Helmut.

Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis by David C. Burgess, Michael.

Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians by Willem J. Remme, John.

Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction by Mortimer Korf-Klingebiel,

The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality by Jane Østergaard.

Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome by Andrea Sarkozy, Tim Boussy, Georgios.

Guidelines on the management of valvular heart disease by Alec Vahanian, Helmut Baumgartner, Jeroen Bax, Eric Butchart, Robert Dion, Gerasimos Filippatos,

Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair.

Excessive heart rate increase during mild mental stress in preparation for exercise predicts sudden death in the general population by Xavier Jouven, Peter.

Guidelines for the diagnosis and management of syncope (version 2009)‏ by,,,,,,,,,,,,, Angel Moya, Richard Sutton, Fabrizio Ammirati, Jean-Jacques Blanc,

Five-year echocardiographic results of combined undersized mitral ring annuloplasty and coronary artery bypass grafting for chronic ischaemic mitral regurgitation.

Indications for the use of diagnostic implantable and external ECG loop recorders by, Michele Brignole, Panos Vardas, Ellen Hoffman, Heikki Huikuri, Angel.

An update on regional variation in cardiovascular mortality within Europe by Jacqueline Müller-Nordhorn, Sylvia Binting, Stephanie Roll, and Stefan N.

European guidelines on cardiovascular disease prevention in clinical practice: executive summary by Ian Graham, Dan Atar, Knut Borch-Johnsen, Gudrun Boysen,

Acute viral myocarditis by Robert Dennert, Harry J. Crijns, and Stephane Heymans EHJ Volume 29(17): August 25, 2008 Published on behalf of the.

Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled,

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 by , Kenneth Dickstein, Alain Cohen-Solal, Gerasimos Filippatos,

Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension.

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,

Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non- compaction, and septal defects by Lorenzo.

Dronedarone in patients with congestive heart failure: insights from ATHENA by Stefan H. Hohnloser, Harry J.G.M. Crijns, Martin van Eickels, Christophe.

Delivery of care for adult patients with congenital heart disease in Europe: results from the Euro Heart Survey by Philip Moons, Peter Engelfriet, Harald.

Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers by Leslee J. Shaw, Paolo Raggi, Tracy Q. Callister, and Daniel.

Comparison of operator radiation exposure with optimized radiation protection devices during coronary angiograms and ad hoc percutaneous coronary interventions.

Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation by Laurens F. Tops, Martin.

High heart rate: a cardiovascular risk factor? by Stéphane Cook, Mario Togni, Marcus C. Schaub, Peter Wenaweser, and Otto M. Hess EHJ Volume 27(20):

Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease by Fabrizio Tomai, Flavio Ribichini,

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Figure 1 Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or ‘natriuretic peptide first’

Evidence-based treatment algorithm, including clinical trials published through A, B, and C are levels of evidence defined as follows—Level of Evidence:

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients Gérald Simonneau, Nazzareno Galiè,

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

Timeline of approval of therapies for pulmonary arterial hypertension.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Compounds acting on pathogenic pathways of pulmonary arterial hypertension. Compounds acting on pathogenic pathways of pulmonary arterial hypertension.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Guidelines for the diagnosis and treatment of pulmonary hypertension by, Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery, Joan Albert Barbera, Maurice Beghetti, Paul Corris, Sean Gaine, J. Simon Gibbs, Miguel Angel Gomez-Sanchez, Guillaume Jondeau, Walter Klepetko, Christian Opitz, Andrew Peacock, Lewis Rubin, Michael Zellweger, Gerald Simonneau,, Alec Vahanian, Angelo Auricchio, Jeroen Bax, Claudio Ceconi, Veronica Dean, Gerasimos Filippatos, Christian Funck-Brentano, Richard Hobbs, Peter Kearney, Theresa McDonagh, Keith McGregor, Bogdan A. Popescu, Zeljko Reiner, Udo Sechtem, Per Anton Sirnes, Michal Tendera, Panos Vardas, Petr Widimsky,, Udo Sechtem, Nawwar Al Attar, Felicita Andreotti, Michael Aschermann, Riccardo Asteggiano, Ray Benza, Rolf Berger, Damien Bonnet, Marion Delcroix, Luke Howard, Anastasia N Kitsiou, Irene Lang, Aldo Maggioni, Jens Erik Nielsen- Kudsk, Myung Park, Pasquale Perrone-Filardi, Suzanna Price, Maria Teresa Subirana Domenech, Anton Vonk-Noordegraaf, and Jose Luis Zamorano EHJ Volume 30(20): October 14, 2009 © The European Society of Cardiology All rights reserved. For permissions please

Diagnostic algorithm. Authors/Task Force Members et al. Eur Heart J 2009;30: © The European Society of Cardiology All rights reserved. For permissions please

Evidence-based treatment algorithm for pulmonary arterial hypertension patients (for group 1 patients only). *To maintain arterial blood O2 pressure ≥8 kPa (60 mmHg). †Under regulatory review in the European Union. §IIa-C for WHO-FC II. APAH = associated pulmonary arterial hypertension; BAS = balloon atrial septostomy; CCB = calcium channel blocker; ERA = endothelin receptor antagonist; IPAH = idiopathic pulmonary arterial hypertension; PDE5 I = phosphodiesterase type-5 inhibitor; WHO-FC = World Health Organization functional class. Authors/Task Force Members et al. Eur Heart J 2009;30: © The European Society of Cardiology All rights reserved. For permissions please